Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have fail...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lacy, Martha Q., Allred, Jacob B., Gertz, Morie A., Hayman, Suzanne R., Short, Kristen Detweiler, Buadi, Francis, Dispenzieri, Angela, Kumar, Shaji, Greipp, Philip R., Lust, John A., Russell, Stephen J., Dingli, David, Zeldenrust, Steven, Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J., Reeder, Craig, Rajkumar, S. Vincent, Mikhael, Joseph R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2011
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291492/
https://ncbi.nlm.nih.gov/pubmed/21690557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348896
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller